Estrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Decline in Short Interest

Estrella Immunopharma, Inc. (NASDAQ:ESLA) was the recipient of a significant decrease in short interest in October. As of October 31st, there was short interest totalling 6,500 shares, a decrease of 57.0% from the October 15th total of 15,100 shares. Approximately 0.1% of the company’s stock are sold short. Based on an average daily volume of 127,000 shares, the days-to-cover ratio is presently 0.1 days.

Estrella Immunopharma Stock Up 5.4 %

Estrella Immunopharma stock traded up $0.04 during mid-day trading on Wednesday, hitting $0.84. The company had a trading volume of 5,995 shares, compared to its average volume of 78,401. The stock has a market cap of $30.40 million, a price-to-earnings ratio of -0.39 and a beta of 0.24. Estrella Immunopharma has a 1 year low of $0.63 and a 1 year high of $3.23. The business has a fifty day moving average of $0.94 and a 200 day moving average of $1.10.

Estrella Immunopharma (NASDAQ:ESLA) last announced its quarterly earnings results on Friday, September 27th. The company reported ($0.13) EPS for the quarter.

About Estrella Immunopharma

Estrella Immunopharma, Inc, a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia.